China Longevity Group Co. Ltd. (HK:1863)
:1863
Want to see HK:1863 full AI Analyst Report?
Top Page
China Longevity Group Co. Ltd.
(1863)
Select Model
Select Model
Rating:51Neutral
Price Target:―
Action:Reiterated
Date:12/30/25
The score is primarily driven by a moderate financial profile: revenue recovery but weaker margins and earnings, increased leverage with lower ROE, and volatile cash generation with negative free cash flow. Technical and valuation inputs were not provided, limiting confidence in momentum and pricing assessments.
Positive Factors
Revenue Growth
The strong revenue rebound indicates a recovery in market demand and potential for future growth, supporting long-term business sustainability.
Negative Factors
Weak Profitability
Declining margins indicate cost pressures or pricing challenges, which can erode earnings and reduce competitive positioning over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The strong revenue rebound indicates a recovery in market demand and potential for future growth, supporting long-term business sustainability.
Read all positive factors
China Longevity Group Co. Ltd. (1863) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)15.8
Beta (1Y)N/A
Revenue Growth3.45%
EPS Growth-20.08%
CountryHK
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryIndustrial Materials
Share Statistics
EPS (TTM)0.06
Shares Outstanding852,612,500
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-1.68
Price to Book (P/B)1.46
Price to Sales (P/S)0.94
P/FCF Ratio-45.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Longevity Group Co. Ltd. Business Overview & Revenue Model
Company Description
China Longevity Group Co Ltd is involved in the reinforced materials business. It engaged in designing, developing, manufacturing, and sale of polymer-processed polyester fabric composite materials, reinforced composite materials, conventional mat...
How the Company Makes Money
The company generates revenue through multiple streams, including the sale of health supplements and herbal products, which are marketed both online and through traditional retail channels. Key revenue streams include direct-to-consumer sales, dis...
China Longevity Group Co. Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.21B | 1.17B | 933.93M | 926.62M | 1.44B | 812.14M |
| Gross Profit | 208.83M | 202.74M | 186.04M | 146.32M | 260.47M | 188.71M |
| EBITDA | 145.06M | 127.29M | 127.75M | 122.09M | 195.87M | 92.27M |
| Net Income | 52.26M | 55.55M | 63.00M | 46.19M | 106.93M | 45.03M |
Balance Sheet | ||||||
| Total Assets | 1.95B | 1.94B | 1.71B | 1.33B | 1.39B | 970.22M |
| Cash, Cash Equivalents and Short-Term Investments | 110.73M | 83.35M | 64.36M | 90.58M | 77.99M | 34.90M |
| Total Debt | 707.91M | 680.75M | 619.57M | 332.50M | 255.45M | 203.23M |
| Total Liabilities | 1.10B | 1.11B | 951.79M | 688.27M | 831.66M | 569.76M |
| Stockholders Equity | 766.55M | 749.28M | 676.42M | 599.34M | 531.17M | 400.47M |
Cash Flow | ||||||
| Free Cash Flow | -19.99M | -23.86M | -354.53M | -138.53M | 55.80M | -87.02M |
| Operating Cash Flow | 167.06M | 103.56M | -10.62M | 35.14M | 177.51M | 28.38M |
| Investing Cash Flow | -188.62M | -135.18M | -333.16M | -95.10M | -201.75M | -115.49M |
| Financing Cash Flow | 69.49M | 50.22M | 317.36M | 73.07M | 67.21M | 95.77M |
China Longevity Group Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$376.45M | 4.98 | 4.28% | 7.10% | -2.78% | -24.77% | |
66 Neutral | HK$1.53B | 4.63 | 39.78% | 9.92% | -23.31% | -44.61% | |
56 Neutral | HK$474.01M | -10.45 | 27.04% | ― | 2.00% | ― | |
54 Neutral | HK$1.48B | 117.78 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ― | 15.80 | 7.11% | ― | 3.45% | -20.08% | |
50 Neutral | HK$497.79M | -20.28 | -10.69% | 1.72% | -3.49% | -1567.01% |
* Healthcare Sector Average
HK:1863
China Longevity Group Co. Ltd.
―
―
―
HK:1830
Perfect Medical Health Management Limited
1.22
-0.93
-43.26%
HK:2138
EC Healthcare
0.42
-0.19
-31.15%
HK:3869
Hospital Corporation of China Ltd
3.43
-1.57
-31.40%
HK:3886
Town Health International Medical Group Ltd.
0.22
-0.02
-7.63%
HK:0722
UMP Healthcare Holdings Limited
0.47
0.08
21.45%
China Longevity Group Co. Ltd. Corporate Events
China Longevity Group Updates on Trading Suspension and Business Health
Oct 31, 2025
China Longevity Group Company Limited, listed on the Stock Exchange of Hong Kong, has announced that its production, operation, and financial health remain stable, with a continued focus on research and development of new materials and products. D...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.